Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Qyuns Therapeutics / Equity Capital Markets

<ul>
<li>Qyuns Therapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$ 100m via a Hong Kong listing.</li>
<li>In this note, we examine the company's core products, namely QX002N, an IL-17A antibody, and QX005N, an IL-4Rα antibody. We also look at the company's management and pre-IPO investors.</li>
<li>We are of mixed views for its two core products. We also think the management and pre-IPO investors are of mediocre quality.</li>
</ul>


Qyuns Therapeutics, a China-based clinical-stage biotechnology company, plans to raise up to US$ 100m via a Hong Kong listing.
In this note, we examine the company's core products, namely QX002N, an IL-17A antibody, and QX005N, an IL-4Rα antibody. We also look at the company's management and pre-IPO investors.
We are of mixed views for its two core products. We also think the management and pre-IPO investors are of mediocre quality.


Qyuns Therapeutics (荃信生物) Pre-IPO: Mixed View on Two Core Products